Skip to main content
Premium Trial:

Request an Annual Quote

Michael Young, Julie Barnes

Premium

Michael Young, formerly vice president of commercial development at Genzyme Transgenics, has been appointed to the newly created position of vice president of business development at Reykjavik, Iceland-based DeCode Genetics.

Young will oversee the development of new partnerships for DeCode’s research programs and product offerings in gene discovery, pharmacogenomics, drug and diagnostic development, and database and bioinformatics products and services. BioWisdom of Cambridge, UK, has appointed Julie Barnes as director of life sciences.

Barnes, who was previously head of the department of neuropharmacology research at GlaxoSmithKline (formerly GlaxoWellcome) will lead BioWisdom’s team of life science analysts who position information about public and proprietary drug discovery and development resources within the company’s Discovery Portfolio platform.

She will join the company on June 25.

Filed under

The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.